Emzor Raises ₦26.7 Billion. Can Nigeria Start Making More of What Goes Into Its Medicines?
DA-X42 · Healthcare · By David Adeniji ·
Emzor Pharmaceutical Industries has raised ₦26.7 billion through a five-year bond, with proceeds supporting manufacturing expansion and completion of its antimalarial API plant in Sagamu.
Today's Signal
Emzor Pharmaceutical Industries has raised ₦26.7 billion through a five-year, 19% fixed-rate bond to support working capital, expand manufacturing capacity and help complete its antimalarial Active Pharmaceutical Ingredient plant in Sagamu, Ogun State.
Money Direction
Bond investors → Emzor Pharmaceutical Industries → working capital and manufacturing expansion → Sagamu API plant → chemicals, laboratory services, equipment, utilities, packaging, warehousing and distribution → pharmaceutical production and skilled employment.
Opportunity Areas
Pharmaceutical manufacturing; active pharmaceutical ingredients; industrial chemicals; laboratory services; packaging; equipment maintenance; utilities; warehousing; distribution; quality assurance and pharmaceutical supply chains.
Skills Signal
Industrial pharmacy, chemistry, microbiology, process engineering, laboratory science, quality control, production technology, pharmaceutical manufacturing, equipment maintenance and supply-chain management.
Who Should Pay Attention
Pharmaceutical manufacturers, chemical suppliers, laboratory businesses, packaging companies, industrial equipment providers, logistics and warehousing businesses, pharmacists, chemists, microbiologists, engineers, technicians and investors interested in Nigerian manufacturing.
Watching Next
Completion and commissioning of the Sagamu API facility, start of commercial production, production volumes, domestic pharmaceutical customers, import substitution achieved, additional products manufactured and the plant's ability to generate returns against its relatively high financing cost.
DA-X42: Emzor Pharmaceutical Industries has raised ₦26.7 billion, and this capital is headed into something Nigeria imports heavily: the ingredients in medicines.
The five-year bond carries a 19% coupon. Proceeds will support working capital, expand local manufacturing and help complete its antimalarial Active Pharmaceutical Ingredient plant in Sagamu, Ogun State.
APIs are the substances that give medicines their therapeutic effect. Nigerian drug manufacturers still depend heavily on imported APIs.
Instead of foreign exchange leaving Nigeria to buy every ingredient abroad, more spending could remain in domestic manufacturing. That creates a chain involving chemicals, packaging, laboratories, quality assurance, equipment maintenance, utilities, warehousing and distribution.
For businesses around the plant, localisation matters because manufacturing creates recurring demand. Production needs inputs, testing, handling and movement.
The skills chain is equally important. Industrial pharmacists, chemists, microbiologists, process engineers, laboratory scientists, quality-control specialists and production technicians become more valuable as local manufacturing deepens.
But there is another number I would not ignore: 19%.
That is the annual coupon on the bond. Emzor has secured long-term naira capital, but it is expensive capital. The new plant must create enough value to carry that financing cost.
The bond has been raised and listed. The plant, however, is not yet commissioned.
So the next milestone is physical, not financial: getting the Sagamu facility into commercial production and seeing how much imported pharmaceutical input it can replace.
Sources
FMDQ Punch Proshare